Phase 2 randomized study of adriamycin and docetaxel in the first-line treatment of locally advanced or metastatic breast cancer patients with measurable primary breast tumor to validate gene expression and proteomic signatures predictive of treatment response.
Latest Information Update: 18 Sep 2021
At a glance
- Drugs Docetaxel; Doxorubicin
- Indications Breast cancer
- Focus Pharmacogenomic; Therapeutic Use
Most Recent Events
- 10 Dec 2013 Biomarkers information updated
- 26 Mar 2012 Actual patient number (49) added as reported by ClinicalTrials.gov.
- 26 Mar 2012 Planned end date (Feb 2014) added as reported by ClinicalTrials.gov.